trial

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

NCTId NCT03817502
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 330 (estimated)
Sponsored by Gedeon Richter Ltd.
Primary completion 2026-12-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
330 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2019-06-06
Primary completion
2026-12-15
Eligibility
ALL · 13 Years · 17 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

Gedeon Richter Ltd.Lead Sponsor

Sites

57 total
Culver City, United StatesAtlanta, United StatesAtlanta, United StatesBloomfield Hills, United StatesFlowood, United StatesBuffalo, United StatesNew York, United StatesCincinnati, United StatesThe Woodlands, United StatesSofia, BulgariaTargovishte, BulgariaBarranquilla, Colombia

Linked catalysts

1
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants ( — primary completion2026-12-15

Facts & assertions

4 sourced
Enrollment
330
Phase
PHASE3
Primary Completion Date
2026-12-15
Status
RECRUITING
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
Gedeon Richter Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication